The fireside chat featured Evan P. Cohen, MD (Montefiore St. Luke’s Cornwall in Newburgh, New York) and John Misdary, MD (Excelis Medical Associates in Tampa, FL), who discussed the stresses and associated healthcare costs psychiatric patients place on emergency department physicians and staff, specifically patients with Acute Suicidal Ideation and Behavior (ASIB).
The discussion was moderated by Michael Cozart, Managing Partner at LifeSci Consulting.
ASIB in Major Depressive Disorder (MDD) has no current FDA-approved therapy, and Seelos Therapeutics (NASDAQ: SEEL), seeks to address this unmet need with their investigational treatment SLS-002, intranasal racemic ketamine.
- Discovering Seelos
- Patients and Caregivers
- Investors and Media